Page 31 - Sanket Koul

Cabinet approves PM-Vidyalaxmi to provide aid to meritorious students

Rs 3,600 crore outlay outlined for the scheme till FY31

Max Healthcare Q2: Net profit up 1.9% at Rs 281.81 cr, revenue rises 25%

Hospital chain's average revenue per occupied bed increases 2% at Rs 76,100

Will launch 3 biosimilars globally in 2-3 years: Biocon Biologics CEO & MD

Shreehas Tambe, MD & CEO, Biocon Biologics talks about refinancing, upcoming launches, and future roadmap, in a virtual interaction

Mankind Pharma Q2 results: PAT rises 29% to Rs 659 crore, revenue up 14%

Mankind's revenue from operations rose to Rs 3,077 crore in Q2 FY25, a 13.6 per cent Y-o-Y rise from Rs 2,708 crore reported in Q2 FY24

Lifestyle changes, lack of screening behind rise in breast cancer cases

The data also suggests that states such as Uttar Pradesh, Maharashtra, and West Bengal had the highest incidences of breast cancer in 2023

Ayushman Bharat expansion to benefit elderly; experts raise key concerns

With rising number of patients, healthcare providers call for timely payments

PM Narendra Modi rolls out health cover for 70-plus senior citizens

Beneficiary base expansion to be done at an outlay of Rs 3,437 crore

Medical device makers claim import of refurbished devices can harm industry

Manufacturing associations added that recent government orders permitting such imports threaten the efforts of Indian manufacturers to meet the vision of Aatmanirbhar Bharat

Torrent Pharma Q2FY25 results: Net profit rises 17%, misses estimates

At an operational level, Torrent Pharma's earnings before interest, tax, depreciation, and amortisation stood at Rs 939 crore, with an Ebitda margin of 32.5 per cent

CDSCO flags 4 drugs as spurious and 48 as not of standard quality

The apex drug regulatory body also listed 48 drugs and formulations, manufactured by 40 companies, as not of standard quality (NSQ)

Strides Pharma Q2 results: Net profit at Rs 93.7 cr, revenue up 20%

US revenue hitting quarterly high, sustained growth across markets among reasons

Mankind completes Rs 13,768 cr acquisition of Bharat Serums and Vaccines

The announcement was made after market hours. On Wednesday, Mankind Pharma's shares closed at Rs 2,529.80 apiece, down 1.46 per cent on the Bombay Stock Exchange (BSE)

Indian population saw 30% increase in ANAs post Covid-19, says study

ANAs are proteins produced by the immune system that mistakenly target the body's own cells, leading to tissue damage and autoimmune diseases like rheumatoid arthritis and thyroid disorders

NOTTO urges states, UTs to act against eye banks not meeting targets

The step comes as NOTTO looks to link all cornea transplant centres and tissue banks, including eye banks, with a national registry database of patients maintained by it

Indian CDMOs could account for up to 10% of global outsourced work by 2033

The survey states that the industry is about to witness a redistribution of outsourcing work across several Asian countries, with India and Korea emerging as new powerhouses by 2033

NPPA raises ceiling prices of 8 scheduled drugs for asthma, TB, glaucoma

Ceiling prices were also revised for the asthma drug Salbutamol in tablets of 2 mg and 4 mg formulations and respirator solution of 5 mg/ml formulation

Faima pauses strike as Bengal govt holds emergency meet with doctors

Doctor's body asks resident doctors associations to be ready to stop elective services in case meeting does not address demands

Southern states dominate authorised hospital admissions under PMJAY

TN, Kerala among top five despite gradual fall in hospital admissions in the last three years

Faima calls for elective services shutdown in hospitals from Monday

Several RDAs and other doctors' associations across India had earlier shut non-urgent elective services for 13 days in August 2024, calling it off after being urged by the Supreme Court

Indian pharma market registers over 5% growth in Sept 2024: Pharmarack

This comes even as the IPM registered a negative unit growth of -2.3 per cent, with only anti-diabetic and urology therapy segments recording significant unit growth of 3.1 per cent and 5.4 per cent